We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
-17.82%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
-$282M
(-19%)
Cap. Flow
+$79.9M
Cap. Flow
% of AUM
6.8%
Top 10 Holdings %
Top 10 Hldgs %
76.08%
Holding
41
New
4
Increased
4
Reduced
7
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MTSR
Metsera Inc
MTSR
|
+$106M |
| 2 |
ORKA
Oruka Therapeutics
ORKA
|
+$10.8M |
| 3 |
Solid Biosciences
SLDB
|
+$10.6M |
| 4 |
Savara
SVRA
|
+$9M |
| 5 |
Surrozen
SRZN
|
+$7.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$24.9M |
| 2 |
4D Molecular Therapeutics
FDMT
|
+$10.7M |
| 3 |
Oric Pharmaceuticals
ORIC
|
+$10.6M |
| 4 |
Aquestive Therapeutics
AQST
|
+$9.36M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$5.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.34% |
| 2 | Financials | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zura Bio
ZURA
$516M
| $6.48M | 0.55% |
5,023,166
+3,000,000
| +148% | +$4.73M |
|
|
ARTV
27
Artiva Biotherapeutics
ARTV
$491M
| $4.83M | 0.41% |
1,609,569
| – | – |
|
28
Trevi Therapeutics
TRVI
$2.59B
| $3.87M | 0.33% |
615,506
-650,951
| -51% | -$3.11M |
|
|
APLT
29
DELISTED
Applied Therapeutics
APLT
| $2.72M | 0.23% |
5,567,709
-4,422,882
| -44% | -$2.6M |
|
|
30
4D Molecular Therapeutics
FDMT
$532M
| $2.19M | 0.19% |
677,600
-2,274,771
| -77% | -$10.7M |
|
|
CASI
31
DELISTED
CASI Pharmaceuticals
CASI
| $2.13M | 0.18% |
987,259
| – | – |
|
32
Tenax Therapeutics
TENX
$363M
| $1.36M | 0.12% |
208,333
| – | – |
|
|
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
| $1.23M | 0.1% |
142,973
-267,339
| -65% | -$4.13M |
|
34
Century Therapeutics
IPSC
$364M
| $1.19M | 0.1% |
2,498,069
-1,459,117
| -37% | -$1.1M |
|
35
Tenaya Therapeutics
TNYA
$161M
| $887K | 0.08% |
1,555,556
| – | – |
|
|
CBIO
36
Crescent Biopharma
CBIO
$537M
| $630K | 0.05% |
30,000
| – | – |
|
37
Instil Bio
TIL
$48.3M
| $576K | 0.05% |
33,177
| – | – |
|
|
38
Aquestive Therapeutics
AQST
$463M
| – | – |
-2,629,786
| Closed | -$9.36M |
|
|
MRUS
39
DELISTED
Merus
MRUS
| – | – |
-592,411
| Closed | -$24.9M |
|
|
TERN
40
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-1,077,090
| Closed | -$5.97M |
|
41
Taysha Gene Therapies
TSHA
$1.68B
| – | – |
-3,225,180
| Closed | -$5.58M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q1 2025 Portfolio in Review
As of Q1 2025, VR Adviser held 41 positions worth $1.18B, down 19% from $1.46B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
VR Adviser deployed $79.9M of net new capital in Q1 2025, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Metsera Inc: 3,750,662 shares worth $102M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was 4D Molecular Therapeutics, an estimated $10.7M trimmed.
- VR Adviser's largest Q1 2025 buy was Metsera Inc: 3,750,662 shares worth $102M.
- VR Adviser added most to Oruka Therapeutics in Q1 2025, an estimated $10.8M increase.
- VR Adviser's biggest Q1 2025 reduction was 4D Molecular Therapeutics, cutting an estimated $10.7M.
- VR Adviser fully exited Merus in Q1 2025, selling an estimated $24.9M.
- VR Adviser's ten largest holdings make up 76% of its $1.18B portfolio in Q1 2025.
- VR Adviser opened 4 new positions and closed 4 in Q1 2025.
- VR Adviser's portfolio value fell 19% quarter-over-quarter to $1.18B.
Based on VR Adviser's 13F filing for Q1 2025, filed 15 May 2025.